| Survivors (n = 96) | Controls (n = 60) | p |
---|---|---|---|
Demographic parameters | |||
 Age (years) | 25.0 ± 5.9 | 23.6 ± 5.8 | 0.16 |
 Sex (M/F) | 54/42 | 30/30 | 0.45 |
 Weight (kg) | 59.1 ± 10.8 | 59.2 ± 11.0 | 0.97 |
 Height (cm) | 166.1 ± 8.7 | 165.9 ± 8.6 | 0.85 |
 Body mass index (kg/m2) | 21.4 ± 3.2 | 21.4 ± 2.6 | 0.99 |
Clinical parameters in survivors | |||
 Age at diagnosis (years) | 8.0 ± 4.8 | ||
 Duration since completion of therapy (years) | 15.4 ± 5.9 | ||
 Cumulative anthracycline dose (mg/m2) | 258 ± 110 (range, 75–675) |  | |
Diagnosis | |||
 Acute lymphoblastic leukaemia | 50 |  |  |
 Non-Hodgkin lymphoma | 15 |  |  |
 Acute myeloid leukaemia | 10 |  |  |
 Osteosarcoma | 4 |  |  |
 Hodgkin lymphoma | 5 |  |  |
 Wilm’s tumour | 6 |  |  |
 Ewing Sarcoma | 2 |  |  |
 Clear cell sarcoma of kidney | 1 |  |  |
 Ganglioneuroblastoma | 1 |  |  |
 Neuroblastoma | 1 |  |  |
 Peripheral primitive neuroectodermal tumour | 1 |  |  |
Need for cardiac irradiation | 5 | Â | Â |
Relapse | 9 | Â | Â |
Cardiac medication | 0 | Â | Â |
Vascular parameters | |||
 Carotid arterial indices | |||
  IMT (mm) | 0.44 ± 0.03 | 0.41 ± 0.02 | < 0.001 |
  Stiffness index | 4.05 ± 0.02 | 3.85 ± 0.61 | < 0.001 |
 Radial pulse waveform indices | |||
  Pulse pressure (mmHg) | 42 ± 8 | 43 ± 9 | 0.34 |
  cSBP (mmHg) | 111 ± 16 | 105 ± 16 | 0.037 |
  rAI (%) | 64 ± 15 | 57 ± 13 | 0.004 |
  rAI at 75 beats/min (%) | 64 ± 14 | 58 ± 12 | 0.009 |